Darren Incorvaia

Darren Incorvaia covers how cutting-edge biology, data and corporate decisions intersect to shape the future of therapeutics. He focuses on the science under the hood of new drugs and platforms, explaining how specific mechanisms, mutations and microbes translate into clinical promise or commercial risk.

Biotech, mechanisms and the next wave of therapeutics

At Fierce Biotech, Incorvaia writes on the companies and technologies that aim to redefine drug development and disease treatment. His coverage of lipoprotein(a) and pelacarsen in a feature on a “diabolical” molecule poised to become biotech’s next gold rush shows his interest in linking molecular targets to large untapped patient populations and investor attention. In that story he walks through how an abnormal lipid particle drives cardiovascular risk and why a targeted antisense therapy could open a major new market.

He reports closely on oncology innovation, including a piece on a drug combination that treats multiple cancers carrying a “paradox” BAP1 mutation in mice. In that article he explains how characterizing an enigmatic mutation revealed new drug targets, and how inhibiting partners such as LSD1 and PARP1 in BAP1-deficient cancers disrupted DNA repair, killed tumor cells and prolonged survival across several cancer types. He brings the same mechanistic lens to vaccine platforms, as in his story on Boehringer Ingelheim licensing Prime Vector Technologies’ viral vector platform for cancer vaccine R&D, where he lays out how an Orf virus-based system might support next-generation immunotherapies.

Even when the subject is metabolic or neuropsychiatric disease, he foregrounds molecular pathways. In his reporting on GLP-1 drugs and depression, he explores how these therapies might affect mood by reshaping the gut microbiome, spotlighting the specific “mood-boosting” microbes and circuits that tie obesity medicines to brain health. Across these pieces, he distinguishes himself by connecting specific molecular levers to clinical endpoints and strategic positioning rather than treating therapeutics as generic products.

AI, genomics and data-driven discovery

Incorvaia regularly covers the role of artificial intelligence and large-scale genomics in drug and target discovery. His article on a deep learning AI model scanning the “dark matter” of global genomic data to identify more than 160,000 potential new RNA virus species, including around 70,000 never-before-seen candidates, exemplifies his approach. He details how the tool scoured tens of terabytes of environmental sequencing data, explains what makes some of the newly identified viruses so divergent they could form many new supergroups, and situates these findings in the broader search for hidden pathogens.

He also writes about AI-designed compounds for conditions such as opioid use disorder, focusing on how models translate patterns in brain circuitry and behavior into candidates that reduce drug intake in animal studies. In these pieces, he spends time on model design and validation, but keeps the emphasis on what matters for therapeutic development: how AI reshapes timelines, risk and the types of biology companies can tackle. His reporting often bridges technical detail with accessible explanations, making complex computational tools legible to readers who need to understand their impact more than their mathematics.

Data governance and access is another recurring thread. His story on the National Institutes of Health banning researchers in countries including China, Russia and Iran from multiple controlled-access databases walks through which resources are affected, the kinds of cancer, neuropsychiatric and adolescent brain data at stake, and the policy rationale tied to safeguarding Americans’ health and genomics information. He treats these decisions as central to the future of global research collaboration and the evidence base biotechs rely on, not as peripheral administrative news.

Restructurings, failures and the business side of science

Incorvaia’s beat extends beyond lab findings into the corporate and financial dynamics that determine whether scientific ideas survive. He contributes to special reports such as the “Biotech Graveyard,” cataloguing companies that have shut down or drastically retrenched and examining the scientific, clinical and funding missteps that led there. His reporting on NGM Bio cutting 75% of staff in a strategic pivot, and on Lykos ending a chaotic week by slashing three-quarters of its workforce after regulatory rejection and paper retractions, follows the full arc from scientific ambition through regulatory scrutiny to restructuring.

These stories are not treated as simple personnel moves. He typically connects workforce cuts and program cancellations to trial outcomes, regulatory signals and investor sentiment, showing how each decision reverberates through pipelines and partner networks. When he covers licensing deals like Boehringer’s viral vector platform acquisition, he places them in the same continuum: a way for companies to hedge bets, replenish platforms and manage risk in an environment where failure is common enough to warrant a dedicated “graveyard” report.

This blend of mechanistic science, data-centric discovery and sober attention to restructurings gives his coverage a distinct texture. Biotech firms in his stories are defined by the specific biology they pursue and the structural pressures they face, rather than by general industry labels.

Role and focus at Fierce Biotech

Incorvaia is a senior writer at Fierce Biotech, part of the Fierce Life Sciences and Healthcare group. His work there spans research, policy and corporate coverage within health and biotechnology, with a particular focus on how molecular insights, AI tools and data policies drive and constrain new therapies. He also contributes to team features on how biotechs navigate challenging market and regulatory climates.

Beyond Fierce Biotech, he has written science, health and environmental stories for other outlets, including major newspapers and science publications, further grounding his reporting in the norms of explanatory science journalism. Across platforms, his recurring interest is making complex biological and data-driven advances understandable without diluting their specificity, while situating them within the economic and regulatory forces that decide which ideas become medicines.